Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood and bone marrow sampling: This intervention involves the collection of peripheral blood before and 3 days after coronary artery bypass grafting (CABG), as well as a one-time collection of bone marrow sample during sternotomy. Samples are analyzed using spectral flow cytometry to characterize the phenotype and maturation stages of circulating and medullary megakaryocytes using a panel of specific surface antibodies.

Study summary

Megakaryopoiesis, the mechanism of blood platelet production, is difficult to assess in clinical practice as it relies solely on microscopic description. Recent studies described the presence of emergency megakaryopoiesis bypassing the classical maturation stages under certain conditions. Circulating megakaryocytes were identified in inflammatory and hemostatic conditions. The aim of this study is to characterize the phenotype of medullar and circulating megakaryocytes by flow cytometry during and after coronary artery bypass grafting.

Eligibility

Primary outcome measure(s)

• Phenotype of bone marrow and circulating megakaryocytes — Day of surgery
  Circulating and bone marrow megakaryocytes will be analyzed using spectral flow cytometry on samples collected during coronary artery bypass surgery. Cells will be labeled with a panel of specific surface antibodies . Megakaryocytes will be classified by maturation stage (multipotent progenitor \[MPP\], common myeloid progenitor \[CMP\], megakaryocyte-erythrocyte progenitor \[MEP\], pro-megakaryocyte \[proMK\], immature megakaryocyte \[imMK\], mature megakaryocyte \[MK\]) and specialization status (specialized MKs).

Trial sites (1)

More University Hospital, Toulouse trials in France